Recently, the BioCartis Idylla Genefusion assay, a rapid testing modality with a turn-around time (TAT) of less than 4 h and technologist hands-on time < 5 min has been introduced to identify targetable, NSCLC-related fusion transcripts (ALK, ROS1, RET, NTRK1-3) and MET exon 14 splice mutations [12,13,14]. The gene discussed is RET; the disease is non-small cell lung carcinoma.